Clinical Trial Search

Primary: The Percent Time With pH <4.0 During 24 Hour Esophageal pH Monitoring at the End of the Observation Period (Predose Monitoring) and at the End of the Treatment Period…

Primary: Number of Patients With Overall Response (Complete Response + Partial Response) — 61; 31 Participants — p=0.00201

Primary: Overall Survival Time (OS) — 11.3; 10.1 months — p=0.0441

Primary: Change in Limb Fat (g) From Baseline — 74; 110 grams — p=0.64

Primary: Change in the Positive and Negative Syndrome Scale (PANSS) Total Score for Schizophrenia — -18.6; -17.9 Scores on a scale

Primary: Change in Hemoglobin (Hb) Concentration From Baseline to the Evaluation Period — 11.29; 11.33; 0.15; -0.03 g/dL

Primary: Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 13 in Forced Expiratory Volume (Liters) in 1 Second (FEV1) — 1.186…

Primary: Overall Survival Time (OS) — 10.1; 7.4 months — p=0.036

Primary: American College of Rheumatology (ACR) 20 Response at Week 14. — 27; 51; 54; 105 participants — p=<0.001

Primary: Proportion of Participants With Complete Response 120 Hours Following Initiation of High-dose Cisplatin Chemotherapy in the Overall Phase of Cycle 1 — 0.696; 0.570…

Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26. — -0.19; -0.66; -0.80 percentage of Glycosylated Hemoglobin — p=<0.001

Primary: Change in HbA1c Level From Baseline to Week 18 (LOCF) — 8.41; 8.28; 7.53; 7.93 Percent

Primary: Time to Progressive Disease (TTPD) by Treatment Schedule — 8.33; 7.51 months — p=0.345

Primary: Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c) — 8.33; 8.33; 7.82; 8.28 percent — p=0.0011

Primary: Number of Participants With an Investigator's Static Global Assessment (ISGA) Score of Clear (0) or Almost Clear (1) for Scalp Involvement at Week 8 Using the Failure…